Immunome, Inc. (IMNM)
Pre-market:
| Previous close | 13.15 |
| Open | 13.15 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 12.80 - 13.47 |
| 52-week range | 5.26 - 30.96 |
| Volume | |
| Avg. volume | 809,785 |
| Market cap | 796.387M |
| Beta (5Y monthly) | 1.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Immunome Announces Completion of Purchase of Assets from Atreca
BOTHELL, Wash., May 20, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the completion of its purchase of antibodies and related assets from Atreca, Inc. Under the terms of the agreement, Immunome paid Atreca $5.5 million upfront, and Atreca will be eligible for up to $7.0 million in clinical development milestones. Immunome received the rights to 28 antibodies as well as certain materi
- Business Wire
Immunome Announces Promotion of Max Rosett to Chief Financial Officer
BOTHELL, Wash., May 17, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the promotion of Max Rosett to Chief Financial Officer, effective May 9. Mr. Rosett most recently held the role of Executive Vice President, Operations, in addition to serving as Immunome’s Interim Chief Financial Officer since January 2024.
- Business Wire
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
BOTHELL, Wash., May 14, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
